- Science
- Clinical Trials
- Guide to Clinical Trials Your participation makes a difference
- Clinical Trials in Children Designed to improve kids' health
- Data and Results Sharing our Results
- Integrity and Transparency Building Trust
- Diversity Equity and Representation
- Plain Language Study Results Trial Result Summaries
- Expanded Access & Compassionate Use Possible Treatment Options
- Find a Trial
- Areas of Focus
- Rare Disease Smaller populations but big impact
- Internal Medicine Extending lifespans worldwide
- Inflammation & Immunology Treatment at the molecular level
- Vaccines Preventing the spread of infections
- Oncology The science of optimism
- Anti Infectives Combatting an evolving risk
- Areas of Innovation
- Gene Therapy Breakthroughs become treatments
- Medicinal Sciences The next generation of science
- Precision Medicine Developing tailored medicines
- Maternal Immunization Protecting newborns at the start
- mRNA Technology Unleashing the next wave of scientific innovations
- Diseases & Conditions
- Coronavirus Resources
- Product Pipeline
- Research Sites
- Clinical Trials
- Products
- How Drugs are Made
- Branded vs. Generic Learn the difference
- Biologics & Biosimilars Cures found in nature
- Commitment to Quality Maintaining the highest standards
- Global Supply Strategic manufacturing locations
- Manufacturing Sites Where medicine is made in the U.S.
- Medicine Safety
- Health Literacy Learning to be well
- Treatment Choices Learning about treatment decisions
- Partnering With Patients Helping others by reporting side effects
- Tips for Patients Preventing medication errors
- Reporting Adverse Events
- Counterfeiting Preventing medication errors
- Product Safety
- Product List
- Product Contacts
- PfizerPro for Professionals
- Patient Assistance Programs
- Distributors
- How Drugs are Made
- Stories
- Newsroom
- About
- People
- Executives Our senior-most leadership
- Board Members The people steering our company
- Scientists Our experts making discoveries
- Patient Stories Our patients
- Colleague Stories Our colleagues
- Responsibility
- Ethics & Compliance Each of us is responsible
- Responsible Business Breakthroughs that change patients’ lives
- Patient Advocacy & Engagement Putting Patients First
- Global Impact Meeting urgent needs worldwide
- Diversity, Equity, and Inclusion Everyone has something to offer
- Environmental Sustainability Our responsiblity to the environment
- Human Rights Furthering dignity and worth
- Health & Safety
- Intellectual Property The benefits of fair competition
- EHS Governance
- Misinformation
- Programs & Policies
- Grants Support for independent research
- Political Partnership Supporting like-minded organizations
- Working with Healthcare Professionals Collaboration to improve lives
- Prescription Value & Pricing How to lower patient costs
- Privacy Principles Commitment to personal data privacy
- Ready for Cures Improving Access to Medicines
- Transparency in Grants Committed to Disclosure
- Policy Positions
- Investors
- Investors Overview Information for stockholders
- Why Invest Why to join us in our mission
- Events & Presentations Calendar of upcoming events
- Financial Reports Quarterly reports and more
- Investor News Announcements about our performance
- Stock Information Charts and data
- Shareholder Services Information on stock transactions
- Corporate Governance
- Corporate Governance Overview Gaining insight into our performance
- Board Committees & Charters Defining the corporate structure
- The Pfizer Board Policies Ensuring ethical leadership
- Corporate Governance FAQs Learn more about our approach
- Contact Our Directors Email any of our Directors
- Purpose
- History
- Careers
- Partners
- People
Pfizer Ventures: How We Work
We actively support our current portfolio companies throughout their growth cycles contributing strategic guidance in addition to capital as well as access to Pfizer expertise, when appropriate.
Read Our 2023 Year in Review Details- With a $900M capital commitment for investment, Pfizer Ventures backs private companies at all stages of development.
- We have a strong focus on early-stage opportunities. But other investments, including start-ups and spinouts, are also considered in scope.
- While primarily U.S. focused, international investments may represent up to 20 percent of the portfolio.
- We can lead or join a syndicate of investors and will seek board representation commensurate with our investment.
- Our investments are focused on potentially transformative therapeutics, with an emphasis in our core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Anti-Infectives and Vaccines.
- We also consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development
- Pfizer Ventures is an active investor, working with management to develop product strategy and shareholder value.
- We bring a pharmaceutical perspective and have the potential to utilize our internal networks and expertise.
- We have a streamlined approval process for investment decisions.
- All investments have the potential for a business relationship with Pfizer.
Key Points
- Focus
- Emphasis primarily on therapeutics (80%)
- Platforms, tools, and technologies with potential to transform drug discovery and development are also considered (20%)
- Geography
- U.S. focused primarily
- Approximately 20 percent of investments may be outside the U.S
- Investment Type
- Direct investing in private companies
- All stages possible, with focus on early stage
- Returns
- Strategic and financial
- Measured over long term
- Funding
- $900M current capital commitment from Pfizer AUM $1.6B
- Up to $20M in first investment; reserved allocation for follow-on investments
- Syndication
- Investing as member of a syndicate
- Syndicate member must be located near company
- Collaboration
- Potential for business relationship with Pfizer considered in investment criteria
- Can be transacted in parallel with investment or explored in the future
- Influence in Development
- Contribute capital and industry experience to help guide development and company growth
- Scientific advisory board participation when appropriate
- Control
- Minority ownership positions
- Board seats where appropriate
- Deal Structure
- Traditional VC investment
- Product rights not required
Our Partners
View a list of current and former companies that we've partnered with.
View Portfolio Details
Our Team Looks Forward to Working with You
Pfizer Partnerships
Submit Your Opportunities
Have an idea? Send us your opportunity for consideration.
Submit Your Opportunity Details